Angioplasty Clinical Trial
— PROMISINGOfficial title:
A Prospective, Multicenter, Observational Study of Short and Long-term Outcome in Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon (PROMISING Study)
There have been a number of randomized controlled studies (RCT) showing the efficacy of the endovascular treatment with drug-coated balloons (DCB) in the femoropopliteal artery lesions. However, these studies have been carefully designed, and most of them have excluded long-length lesions and severely calcified lesions. In addition to being used alone in the real word, drug-coated balloons (DCB) are also used in combination with stents or debulking devices, but in these randomized controlled studies (RCT) they are only compared with standard percutaneous transluminal angioplasty (PTA). Therefore, the investigators initiated this study, which is a prospective, multicenter, observational real-world study of short and long-term outcome in endovascular treatment of femoropopliteal arterial occlusive lesions with DCB.
Status | Active, not recruiting |
Enrollment | 2000 |
Est. completion date | February 1, 2027 |
Est. primary completion date | February 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Rutherford grade 2-5. 2. Femoral popliteal artery stenosis or occlusion, a clear outflow tract no less than 10cm long at the distal end of the knee should be continuous with a clear outflow tract under the ankle. 3. Patients who understand the purpose of this study, volunteer to participate in the experiment, sign informed consent and are willing to follow up. 4. The guide wire needs to pass through the lesion. 5. Life expectancy> 24 months. 6. Patients with thrombosis of the lower extremities, patients who received drug-coated balloon (DCB) intervention after thrombus removal through mechanical thrombus removal, percutaneous catheter thrombolysis, and thrombus removal. 7. Patients who have received DCB intervention for both lower limbs can be enrolled in the group according to the intracavitary treatment time. 8. There is at least one continuous infrapopliteal outflow artery or obtained through intravascular reconstruction. 9. For combined aortic iliac artery disease, the blood flow can be recanalized after intravascular reconstruction without residual stenosis exceeding 50%. Exclusion Criteria: 1. Patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage or myocardial infarction within 3 months before enrollment. 2. Patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc. 3. Patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months. 4. Pregnant and lactating women. 5. Patients who are unable or unwilling to participate in this trial. 6. Patients with Berg's disease. 7. Patients who have undergone arterial bypass on the treatment side. |
Country | Name | City | State |
---|---|---|---|
China | Xuanwu Hospital Capital Medical University | Beijing | |
China | Hospital of Chengdu University of Traditional Chinese Medicine | Chengdu | |
China | Hangzhou First People's hospital of Medical College of Zhejiang University | Hangzhou | |
China | the First Affiliated hospital of Medicine College of Zhejiang University | Hangzhou | |
China | Qingdao Haici hospital affiliated to Qingdao University | Qingdao | |
China | Renji Hospital of Shanghai Jiaotong University | Shanghai | |
China | Zhongshan Hospital of Fudan University | Shanghai | |
China | the second Affiliated Hospital of Medical College of Suzhou University | Suzhou | |
China | Zibo Feng | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology | Chengdu University of Traditional Chinese Medicine, First People's Hospital of Hangzhou, Qingdao University, RenJi Hospital, Second Affiliated Hospital of Suzhou University, Xuanwu Hospital, Beijing, Zhejiang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Freedom from clinically-driven target lesion revascularization(CD-TLR) rate at post-interventional | Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention within the target lesion due to symptoms or drop of ankle brachial index (ABI) of =20% or >0.15 when compared to post-procedure baseline. | 48 months | |
Primary | Major adverse events | Operation-related acute thrombosis, arterial embolism, major amputation and all-cause mortality. | 48 months | |
Secondary | Changes of the patency rate of target lesions at post-interventional | The patency rate of target(Femoropopliteal) lesions would be determined by vascular ultrasound,Restenosis would be diagnosed if the peak systolic velocity ratio(PSVR)=2. 5. | 1 month, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months | |
Secondary | Technical success rate | Successfully revascularize the target vessel. The residual stenosis is <30% and there is no acute thrombosis occurred in the target vessel within 1 week post-operation. | 1 week | |
Secondary | Vascular quality of life questionnaire(VascuQol) | The VascuQol was designed as a questionnaire containing five domains: pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items) to evaluate Health related quality of life (HRQL). Every item has seven response options, with scores ranging from 1 to 7. A total score is the sum of all 25 item scores divided by 25.And both the total score as well as the domain scores range from 1 (worst HRQL) to 7 (best HRQL).The lower the value, the poorer the quality of life. | 1 month, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months | |
Secondary | The patient's ulcer healing | Ulcer healing in patients with Rutherford grade 5 | 1 month, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months | |
Secondary | Freedom from clinically-driven target lesion revascularization(CD-TLR) rate at post-interventional | Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention within the target lesion due to symptoms or drop of ankle brachial index (ABI) of =20% or >0.15 when compared to post-procedure baseline. | 1 month, 3 months, 6 months, 12 months, 24 months, 36 months | |
Secondary | Major adverse events | Operation-related acute thrombosis, arterial embolism, major amputation and all-cause mortality. | 1 month, 3 months, 6 months, 12 months, 24 months, 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02837744 -
Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
|
||
Completed |
NCT02214082 -
Safety of Same Day Discharge After Elective Percutaneous Coronary Intervention
|
N/A | |
Recruiting |
NCT00370578 -
Aspiration Device in Myocardial Infarction Trial
|
N/A | |
Recruiting |
NCT02276846 -
Palpitate-Eluting Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesion Evaluated by OCT
|
N/A | |
Recruiting |
NCT01080638 -
Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.
|
Phase 4 | |
Completed |
NCT03673254 -
Evaluation of Practices and Prognostic Factors of Percutaneous Coronary Interventions (PCI) of Calcified Complex Lesions Using Rotational Atherectomy Device.
|
||
Completed |
NCT01180517 -
The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations
|
Phase 4 | |
Completed |
NCT01249027 -
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
|
||
Completed |
NCT00399646 -
Evaluation of the Metricath Gemini System, a Device Intended to Make Arterial Measurements and Perform Angioplasty Dilations.
|
Phase 2 | |
Recruiting |
NCT05113407 -
Observatory on the Use of the Shockwave Medical C2 Coronary Lithotripsy System in the General Population in France.
|
||
Completed |
NCT04445480 -
Popliteal Block for Lower Limb Angioplasty
|
N/A | |
Completed |
NCT02722213 -
Mindfulness & Stress Management Study for Cardiac Patients
|
N/A | |
Completed |
NCT00858715 -
Resistance to Antithrombotic Therapy
|
N/A | |
Recruiting |
NCT04325867 -
Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19
|
N/A | |
Completed |
NCT01174472 -
Drug Eluting Balloon Angioplasty for Dialysis Access Treatment
|
Phase 2/Phase 3 | |
Terminated |
NCT00289601 -
Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty
|
Phase 4 | |
Completed |
NCT00715416 -
PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents
|
Phase 4 | |
Terminated |
NCT00437905 -
Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial
|
Phase 4 | |
Completed |
NCT01894152 -
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
|
||
Completed |
NCT00808717 -
Efficacy of High Dose atorvaSTATIN Loading Before Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction (STATIN STEMI)
|
Phase 4 |